Gadoterate meglumine

(Dotarem®)

Dotarem®

Drug updated on 11/10/2023

Dosage FormInjection (intravenous; 0.5 mmol/mL containing 376.9 mg/mL gadoterate meglumine)
Drug ClassGadolinium-based contrast agent
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Product Monograph / Prescribing Information

Document TitleYearSource
Dotarem (gadoterate meglumine) Prescribing Information.2022Guerbet LLC, Princeton, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
ACR manual on contrast media. 2021American College of Radiology